Natera GAAP EPS of -$0.64 misses by $0.27, revenue of $592.2M beats by $77.43M

* Natera press release [https://seekingalpha.com/pr/20297814-natera-reports-third-quarter-2025-financial-results] (NTRA [https://seekingalpha.com/symbol/NTRA]): Q3 GAAP EPS of -$0.64 misses by $0.27.
* Revenue of $592.2M (+34.7% Y/Y) beats by $77.43M.
* Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024, an increase of 15.2%.
* Performed approximately 211,000 oncology tests in the third quarter of 2025, compared to approximately 137,100 in the third quarter of 2024, an increase of 53.9% . This included record sequential growth of approximately 21,500 clinical molecular residual disease (MRD) units compared to the second quarter of 2025.
* Raising 2025 annual revenue guidance by $160 million at the midpoint, from $2.02 billion - $2.10 billion to $2.18 billion - $2.26 billion.
* Shares +3%.

MORE ON NATERA

* Natera, Inc. (NTRA) Discusses Findings from ESMO Congress - Slideshow [https://seekingalpha.com/article/4835088-natera-inc-ntra-discusses-findings-from-esmo-congress-slideshow]
* Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript [https://seekingalpha.com/article/4832444-natera-inc-ntra-discusses-findings-from-esmo-congress-transcript]
* Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4825518-natera-inc-ntra-presents-at-bernstein-2nd-annual-global-healthcare-conference-transcript]
* ClearBridge Growth Strategy Fund Buys RBLX, NTRA and XPO; exits UNH, ACN [https://seekingalpha.com/news/4504263-clearbridge-growth-strategy-fund-buys-rblx-ntra-and-xpo-exits-unh-acn]
* NeoGenomics rallies after court win in Natera patent dispute [https://seekingalpha.com/news/4490420-neogenomics-stock-up-court-win-natera]